Aetna
AetnaHome Help Search Contact Us
Aetna TitleSkip the section navigation barAlphabetical ViewWhat's NewAbout Pharmacy Clinical Policy Bulletins
 
    Document Utilities
Print this page
Home  >  Clinical Policy Bulletins  >  Pharmacy  >  Inhaled Anti-Inflammatory Agents
 

Pharmacy Clinical Policy Bulletins

Subject: Inhaled Anti-Inflammatory Agents

Class Edit Summary*
Status Drug PR PR-QL PR-AL ST M EX‡
P Advair Discus® (salmeterol/fluticasone)          
P Asmanex® (mometasone)          
P Flovent® /HFA®/Flovent® Rotadisk® (fluticasone)          
P Pulmicort Respules® (budesonide)          
FE Aerobid /Aerobid M® (flunisolide)         X
FE Azmacort® (triamcinolone)         X
FE Intal® (cromolyn sodium)         X
FE Pulmicort Turbuhaler® (budesonide)         X
FE QVAR® (beclomethasone HFA)         X
FE Tilade® (nedocromil sodium)         X

*P = Preferred; FE = Formulary Excluded; NP = Nonpreferred PR = Precertification; QL = Quantity Limits; AL = Age Limits; ST = Step-Therapy ‡M EX = Medical Exception - This means the physician or health care professional must obtain a medical exception from Aetna, in order for the medication to be eligible for coverage. Medical Exception criteria apply to Formulary Excluded drugs for members enrolled in or covered by closed benefits plans, and also apply to Step-Therapy drugs in cases where a member's physician believes it is medically necessary for the member to use a step-therapy drug in the first instance without a trial of the prerequisite alternative drug(s).

Important Note

This Pharmacy Clinical Policy Bulletin expresses Aetna's determination of whether certain services or supplies are medically necessary. Aetna has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). Aetna expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefits plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their health care providers will need to consult the member's benefits plan to determine if there are any exclusions or other benefit limitations applicable to this service or supply. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (that is, will be paid for by Aetna) for a particular member. The member's benefits plan determines coverage. Some plans exclude coverage for services or supplies that Aetna considers medically necessary. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the federal government or CMS for Medicare and Medicaid members. CMS's Coverage Issues Manual can be found on the following website: http://cms.hhs.gov/manuals/pub06pdf/pub06pdf.asp.

Policy

  1. Medical Exception Criteria

    Aerobid/Aerobid M, Azmacort, Pulmicort Turbuhaler, QVAR, Intal and Tilade are currently listed on the Aetna Formulary Exclusions List.* Therefore, they are excluded from coverage for members enrolled in prescription drug benefits plans that use a closed formulary, unless a medical exception is granted. Aetna considers Aerobid/Aerobid M, Azmacort, Pulmicort Turbuhaler, QVAR, Intal and Tilade to be medically necessary for those members who meet ANY of the following criteria:

    A documented:

    • Contraindication to one preferred inhaled anti-inflammatory agent for asthma OR
    • Intolerance to one preferred inhaled anti-inflammatory agent for asthma OR
    • Allergy to one preferred inhaled anti-inflammatory agent for asthma OR
    • Failure of an adequate trial of one month of one preferred inhaled anti-inflammatory agent for asthma.

*Information regarding Aetna's Preferred Drug List, Formulary Exclusions list, Precertification and Step-Therapy lists is available on our website. In addition, members should refer to their plan documents and may call the toll-free telephone number on their ID card for information regarding their benefits. Health care professionals also may obtain information by calling the Pharmacy Management Precertification Unit at 1-800-414-2386, or they can register to use our password-protected provider website. Visit www.aetna.com, select "Doctors & Hospitals" and choose "Physician Self-Service." Once registration is completed, health care professionals may use our online Precertification/medical exception email request form.

The lists above are subject to change. Not all programs - for example step-therapy, precertification, and quantity limits - are available in all service areas (for example, step-therapy does not apply to fully insured New Jersey members).

Many medications on the Preferred Drug List are subject to manufacturer rebate arrangements between Aetna and the manufacturer of those medications. If the member's prescription benefits plan has a deductible or copay levels based on a percentage of Aetna's contracted rate with the participating pharmacy, the contracted rate does not include or reflect any manufacturer rebate arrangements between Aetna and the medication manufacturer. In prescription plans with a deductible or copayment or coinsurance tiers, use of drugs from the Preferred Drug List generally will result in lower costs to members. However, where the prescription plan utilizes a deductible or copayments or coinsurance calculated on a percentage basis, there could be some circumstances in which a preferred drug would cost the member more than a nonpreferred drug because (1) the negotiated pharmacy payment rate for the preferred drug may be more than the negotiated pharmacy payment rate for the nonpreferred drug, and (2) rebates received by Aetna from drug manufacturers are not reflected in the cost of a prescription drug obtained by a member. The Preferred Drug List is subject to change.

In evaluating clinically and therapeutically similar drugs for selection for the Preferred Drug List, Aetna reviews the costs of drugs and takes into account rebates negotiated between Aetna and drug manufacturers. Consequently, a drug may be included on the Preferred Drug list that is more expensive than a nonpreferred alternative before any rebates Aetna may receive from a drug manufacturer are taken into account. In addition, certain drugs may be chosen for "preferred" status because of their clinical or therapeutic advantages or level of acceptance among physicians even though they cost more than nonpreferred alternatives. The net cost to a self-funded plan sponsor for covered prescriptions will vary based on (1) the terms of Aetna's arrangements with participating pharmacies; (2) the amount of the member's copayment, coinsurance or deductible obligation under the terms of the plan; and (3) the percentage, if any, of rebates to which the plan sponsor is entitled under its agreement with Aetna. As a result, a self-funded plan sponsor's actual claim expense per prescription for a particular preferred drug may in some circumstances be higher than for a nonpreferred alternative.

For members in Texas, additions to the 2006 Preferred Drug List will be effective no later than January 1, 2006. In accordance with state law, fully insured members in Texas who are receiving coverage for medications that are removed from the Preferred Drug List during the plan year will continue to have those medications covered at the same benefit level until their plan's renewal date.

This definition of precertification is not the same as the definition used by Texas law. Our use of the term "precertification" relates to the prior authorization of your services by Aetna, based on our decision of whether the service is medically necessary. Precertification is not a guarantee of payment or "verification" as defined by Texas law.

California HMO members enrolled in a closed formulary benefits plan who are receiving coverage for medications that are moved to the Formulary Exclusions List, and California HMO members who are receiving coverage for medications added to the Precertification or Step-Therapy lists, will continue to have those medications covered, for as long as the treating physician continues prescribing them. This coverage, in accordance with state law, is only provided when the drug is appropriately prescribed and is considered safe and effective for treating the member's medical condition.

Nothing in this section shall preclude the prescribing health care professional from prescribing another drug covered by the plan that is medically appropriate for the enrollee, nor shall anything in this section be construed to prohibit generic drug substitutions.

Place of Service:

    Outpatient

The above policy is based on the following references:

  1. National Institutes of Health, National Heart, Lung and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report Number 2: Guidelines for the Diagnosis and Management of Asthma. Clinical Practice Guidelines. NIH Publication No. 97-4051. Bethesda, MD: NIH, July 1997.
  2. National Institutes of Health, National Heart, Lung and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. Clinical Practice Guidelines. NIH Publication No. 02-5075. Bethesda, MD: NIH, July 2002. http://www.nhlbi.nih.gov/guidelines/asthma/index.htm
  3. Global Initiative For Asthma (GINA), Global Strategy for Asthma Management and Prevention, NHLBI/WHO Workshop Report, 1998. www.ginasthma.com
  4. Pediatric Asthma: Promoting Best Practice Guide for Managing Asthma in Children 1999. AAA/NHLBI NAEPP/AAP collaborative. www.aaaai.org/members/resources/initiatives/
    pediatricasthma.stm
  5. ICSI Health Care Guideline: Diagnosis and management of asthma. Rochester, MN: Institute for Clinical Systems Improvement. May 2002. http://www.icsi.org/knowledge/detail.asp?catID=29&itemID=162. accessed March 1, 2003.
  6. Apter AJ. Clinical advances in adult asthma. J Allergy Clin Immunol. 2003;111:S780-4.
  7. Lemanske Jr FR, Busse WW. Asthma. J Allergy Clin Immunol. 2003;111:S502-19.
  8. Spahn JD, Szefler SJ. Childhood asthma: New insights into management. J Allergy Clin Immunol. 2002;109:3-13.
  9. Kwong KYC, Jones CA. Chronic asthma therapy. Pediatr Rev.1999;20:327-34.
  10. Drugs for asthma. Med Lett Drugs Ther. 2000;42(1073):19-24.
  11. Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001;344:350-62.
  12. Clark DJ, Lipworth BJ. Dose-response of inhaled drugs in asthma: an update. Clin Pharmacokinet. 1997;32:58-74.
  13. Kamada AK, Szefler SJ, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med. 1996;153:1739-48.
  14. Sorkness CA. Establishing a therapeutic index for the inhaled corticosteroids: Part II comparisons of systemic activity and safety among different inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:S52-S64.
  15. FDA Talk Paper: FDA requires new pediatric labeling for inhaled, intranasal corticosteroids. T98-79; November 9, 1998.
  16. O'Byrne PM, Pedersen S. Measuring efficacy and safety of different inhaled corticosteroid preparations. J Allergy Clin Immunol. 1998;102:879-86.
  17. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:S36-S51.
  18. Ferguson AC, Spier S, Manjra A, et al. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134:422-7.
  19. Barnes N. Relative safety and efficacy of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S460-S464.
  20. Robinson DS, Geddes, DM. Inhaled corticosteroids: benefits and risks. J Asthma. 1996;33:5-16.
  21. Allen DB, Mullen, M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 1994;93:967-76.
  22. Clark DJ, Lipworth BJ. Dose-response of inhaled drugs in asthma: an update. Clin Pharmacokinet. 1997;32:58-74.
  23. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med. 1999;159:941-55.
  24. Ledford DK. Adverse effects of inhaled glucocorticoids. Immunol Allergy Clin N Am. 1999;19:819-36.
  25. Clark DJ, Lipworth BJ. Dose-response of inhaled drugs in asthma: an update. Clin Pharmacokinet. 1997;32:58-74.
  26. Adams N, Bestall JM, Jones PW Fluticasone versus beclomethasone or budesonide for chronic asthma (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
  27. van der Wouden JC, Tasche MJA, Bernsen RMD, Uijen JHJM, de Jongste JC, Ducharme FM Inhaled sodium cromoglycate for asthma in children (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
  28. Spooner CH, Spooner GR, Rowe BH Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd
  29. Spooner CH, Saunders LD, Rowe BH Nedocromil sodium for preventing exercise-induced bronchoconstriction (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
  30. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:326-34.
  31. Crowley S. Inhaled glucocorticoids and adrenal function: an update. Paediatr Respir Rev 2003;4:153-61.
  32. Kelly HW, et al. Growth and bone density in children with mild-moderate asthma: a cross-sectional study in children entering the Childhood Asthma Management Program (CAMP). J Pediatr. 2003;143:286-91.
  33. Orefice U, Struzzo P, Dorigo R, Peratoner A. Long term treatment with sodium cromoglycate, nedocromil sodium and beclomethasone dipropionate reduced bronchial hyperresponsiveness in asthmatic subjects. Respiration 1992;59:97 101.
  34. Konig P, Hordvik NL, Kreutz C. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise induced asthma (EIA) in adults. J Allergy Clin Immunol 1987;79:64 68.
  35. Morton AR, Ogle SL, Fitch KD. Effects of nedocromil sodium, cromolyn sodium, and a placebo in exercise induced asthma. Ann Allergy 1992;68:143 148.
  36. Svendsen UG, Frolund L, Madsen F, Nielsen NH. A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms, and bronchial responsiveness in patients with asthma. J Allergy Clin Immunol. 1989;84:224 231.
  37. Bel EH, Timmers MC, Hermans J, Dijkman JH, Sterk PJ. The long term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990;141:21 28.
  38. Harper GD, Neill P, Vathenen AS, Cookson JB, Ebden P. A comparison of inhaled beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma. Respir Med 1990;84:463 469.
  39. Orefice U, Struzzo P, Dorigo R, Peratoner A. Long term treatment with sodium cromoglycate, nedocromil sodium and beclomethasone dipropionate reduced bronchial hyperresponsiveness in asthmatic subjects. Respiration 1992;59:97 101.
  40. Bergman KC, Overlack A. A placebo-controlled, blind comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma. Curr Med Res Opin 1989;11:533:542.
  41. Matthys H, Nowak D, Hader S, Kunkel G. Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 mcg/day delivered as an extrafine aerosol in adults with moderate asthma. Respir Med. 1998;92(suppl A):17-22.
  42. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215-22.
  43. Gross G, Thompson PJ, Chervinsky P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mcg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mcg, for the treatment of moderate asthma. Chest. 1999;115:343-51.
  44. Demedts M, Cohen R, Hawkinson R. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract. 1999;53:331-8.
  45. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HRA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-53.
  46. VandenBurgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoralkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209-26.
  47. Fireman P, Prenner BM, Vincken W, et al. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol. 2001;86:557-65.
  48. Aerobid, Aerobid-M, Product Information. Forest Pharmaceuticals, St Louis, MO. March 2002.
  49. Azmacort Product Information. Aventis Pharmaceuticals Inc., Bridgewater, NJ. May 2003.
  50. Pulmicort Turbuhaler Product Information. AstraZeneca, Wayne, PA. December 2003.
  51. QVAR Product Information. 3M Pharmaceuticals, Northridge, CA. May 2002.
  52. Asmanex Product Information. Schering Corporation, Kenilworth, NJ. May 2005.
  53. Flovent Diskus Product Information. GlaxoSmithKline, Research Triangle Park, NC. July 2005.
  54. Flovent HFA Product Information. GlaxoSmithKline, Research Triangle Park, NC. June 2005.
  55. Intal Product Information. King Pharmaceuticals, Inc., Bristol, TN. February 2004.
  56. USPDI Drug Information for the HealthCare Professional (online). Thomson MICROMEDEX, Greenwood Village, Colorado; 2004.
  57. McEvoy GK, editor. AHFS Drug Information (online). American Society of Health-Systems Pharmacists, Bethesda, Maryland; 2004.
  58. Olin BR, editor. Drugs Facts and Comparisons (electronic online version). St. Louis: J.B. Lippincott Company, 2004.
  59. Medical Economics, Inc., PDR Electronic Library. Thomson Medical Economics, Montvale, NJ; 2003.

Property of Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

January 1, 2006